InSilico Medicine (HKG:3696) invested $105 million in wealth management products offered by CMB International and JPMorgan, according to a Hong Kong bourse filing Thursday.

The AI-driven drug discovery firm invested $50 million in a money market fund managed by CMB International Asset Management with an expected 3.99% annualized rate of return; $50 million in a variable net asset value money market fund by JPMorgan Asset Management with an expected 3.85% annualized rate of return; and a further $5 million in a dual-currency deposit issued by JPMorgan Chase Bank with an expected 4.68% rate of return.

The subscriptions were made with the view of "enhancing returns on surplus cash," the firm said.